[go: up one dir, main page]

HUP0300725A3 - Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors - Google Patents

Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Info

Publication number
HUP0300725A3
HUP0300725A3 HU0300725A HUP0300725A HUP0300725A3 HU P0300725 A3 HUP0300725 A3 HU P0300725A3 HU 0300725 A HU0300725 A HU 0300725A HU P0300725 A HUP0300725 A HU P0300725A HU P0300725 A3 HUP0300725 A3 HU P0300725A3
Authority
HU
Hungary
Prior art keywords
treatment
insulin resistance
resistance syndrome
pde5 inhibitors
cgmp pde5
Prior art date
Application number
HU0300725A
Other languages
Hungarian (hu)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030649A external-priority patent/GB0030649D0/en
Priority claimed from GB0106468A external-priority patent/GB0106468D0/en
Priority claimed from GB0106465A external-priority patent/GB0106465D0/en
Priority claimed from GB0117134A external-priority patent/GB0117134D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of HUP0300725A2 publication Critical patent/HUP0300725A2/en
Publication of HUP0300725A3 publication Critical patent/HUP0300725A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
HU0300725A 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors HUP0300725A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22492800P 2000-08-11 2000-08-11
GB0030649A GB0030649D0 (en) 2000-12-15 2000-12-15 Treatment of the insulin resistance syndrome
US26608301P 2001-02-02 2001-02-02
GB0106468A GB0106468D0 (en) 2001-03-15 2001-03-15 Treatment of diabetes mellitus
GB0106465A GB0106465D0 (en) 2001-03-15 2001-03-15 Treatment of the insulin resistance syndrome
GB0117134A GB0117134D0 (en) 2001-07-13 2001-07-13 Treatment of the insulin resistance syndrome
PCT/IB2001/001428 WO2002013798A2 (en) 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Publications (2)

Publication Number Publication Date
HUP0300725A2 HUP0300725A2 (en) 2003-11-28
HUP0300725A3 true HUP0300725A3 (en) 2005-11-28

Family

ID=27546614

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300725A HUP0300725A3 (en) 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Country Status (9)

Country Link
EP (1) EP1307183A2 (en)
JP (1) JP2004506009A (en)
KR (1) KR20030023747A (en)
CN (1) CN1446084A (en)
AU (1) AU2001276607A1 (en)
CA (1) CA2419033A1 (en)
HU (1) HUP0300725A3 (en)
IL (1) IL154158A0 (en)
WO (1) WO2002013798A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002226633A1 (en) * 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
US6933127B2 (en) 2001-07-05 2005-08-23 Eucro European Contract Research Gmbh & Co. Kg Substrate for PP2C
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
KR20040053210A (en) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
CA2475377A1 (en) * 2002-02-07 2003-08-14 Pfizer Inc. Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
JP2004018524A (en) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg Method for treating arteriosclerosis
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
MXPA05009242A (en) * 2003-03-17 2006-04-18 Pfizer Prod Inc Treatment of type 1 diabetes with pde5 inhibitors.
CN100439371C (en) * 2003-04-29 2008-12-03 辉瑞大药厂 5, 7-diaminopyrazolo [4, 3-d ] pyrimidines useful in the treatment of hypertension
MXPA05011643A (en) 2003-04-29 2005-12-15 Pfizer Ltd 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension.
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0509731A (en) 2004-04-07 2007-09-25 Pfizer pyrazol [4,3-d] pyrimidines
NZ560269A (en) 2005-03-08 2010-12-24 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
EP1909793A2 (en) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
MX2009002282A (en) 2006-09-07 2009-03-20 Nycomed Gmbh Combination treatment for diabetes mellitus.
EA021544B1 (en) 2007-06-04 2015-07-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити TRIARY AREAS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AT512084A1 (en) 2011-10-20 2013-05-15 Univ Wien Tech DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 glycosylation isoforms
CN108452311A (en) * 2012-11-13 2018-08-28 纽斯尔特科学公司 Composition for enhancing energetic supersession and method
AU2014202625B2 (en) 2013-05-14 2018-11-08 Scimar Ltd. Hepatic insulin sensitizing substance and test meal for insulin sensitization
EA201690938A1 (en) 2013-11-05 2016-11-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити COMPOUNDS FOR THE TREATMENT OF DIABETES AND COMPLICATIONS ARISING OUT OF THIS DISEASE
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. DOSAGE FORMS OF TISSUE KALLIKREIN 1
MX2017016930A (en) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Method of treatment of diabetic foot ulcers.
KR102068299B1 (en) * 2018-12-21 2020-01-20 한국기초과학지원연구원 A pharmaceutical composition for prevention or treatment of metabolic disease comprising CYP4A inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
DK0882718T3 (en) * 1995-12-28 2005-12-12 Astellas Pharma Inc benzimidazole
ID22834A (en) * 1997-04-25 1999-12-09 Pfizer PIRAZOLOPIMIDINONA FOR SEXUAL ARRANGEMENT
BR9810456A (en) * 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Sulfonamide compound, method for obtaining it and its pharmaceutical use
EP1070705A4 (en) * 1998-04-06 2002-04-17 Fujisawa Pharmaceutical Co Indole derivatives
KR20010086593A (en) * 1998-12-04 2001-09-13 후지야마 아키라 Sulfonamide Compounds and Uses Thereof as Medicines
KR20020015030A (en) * 1999-03-22 2002-02-27 스티븐 비. 데이비스 Fused Pyridopyridazine Inhibitors of cGMP Phosphodiesterase
DE19944161A1 (en) * 1999-09-15 2001-03-22 Bayer Ag New combination for the treatment of sexual dysfunction
ES2211454T3 (en) * 1999-09-30 2004-07-16 Pfizer Products Inc. PIRROLILAMIDS AS INHIBITORS OF THE FOSFORILASA COLLAGEN.
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
JP2004506009A (en) 2004-02-26
WO2002013798A2 (en) 2002-02-21
IL154158A0 (en) 2003-07-31
HUP0300725A2 (en) 2003-11-28
CA2419033A1 (en) 2002-02-21
CN1446084A (en) 2003-10-01
WO2002013798A3 (en) 2003-01-23
KR20030023747A (en) 2003-03-19
AU2001276607A1 (en) 2002-02-25
EP1307183A2 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
IL154158A0 (en) Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
IL161155A0 (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
AU2003282506A8 (en) Catheter with joinable lumens
IL183922A0 (en) Pyrid - 2 - one derivatives and pharmacetical compostions containing the same
PL392790A1 (en) Pyrazole [3, 4-b] pyridine compounds and the use thereof as phosphodiesterase inhibitors
ZA200207650B (en) Absorbent structure and absorbent articles containing the absorbent structure.
MXPA03009220A (en) Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors.
IL174512A0 (en) Pyrazolo and imidazo-pyrimidine derivatives
IL157662A0 (en) N-but-3-enyl norbuprenorphine and its use as analgesic
EP1575582A4 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
IL175020A0 (en) Chemokine variants and their use
AU2002331726A8 (en) Absorbent article with captured leg elastics
PL368975A1 (en) Absorbent article with improved fit
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
HUP0400464A3 (en) Adenosine analogues for treatment of the insulin resistance syndrome and diabetes
ZA200210316B (en) Composition and its therapeutic use.
PL370272A1 (en) Absorbent structure, and absorbent article containing the absorbent structure
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
EP1407771A4 (en) Sophoridine and use thereof as an analgesic
MY137954A (en) Absorbent structure and absorbent article comprising the absorbent structure
PL372534A1 (en) The treatment of pain with ifendropil
GB0225364D0 (en) Absorbent article comprising an absorbent structure
GB0212573D0 (en) Improved game and article for use with the game
GB0326477D0 (en) Medicaments for use in promoting and maintaining abstinence
GB0030649D0 (en) Treatment of the insulin resistance syndrome

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees